Cargando…

Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons

C-reactive protein (CRP), the prototype human acute phase protein, may be causally involved in various human diseases. As CRP has appeared much earlier in evolution than antibodies and nonetheless partly utilizes the same biological structures, it is likely that CRP has been the first antibody-like...

Descripción completa

Detalles Bibliográficos
Autores principales: Torzewski, Jan, Brunner, Patrizia, Ries, Wolfgang, Garlichs, Christoph D., Kayser, Stefan, Heigl, Franz, Sheriff, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999816/
https://www.ncbi.nlm.nih.gov/pubmed/35407379
http://dx.doi.org/10.3390/jcm11071771
_version_ 1784685281294680064
author Torzewski, Jan
Brunner, Patrizia
Ries, Wolfgang
Garlichs, Christoph D.
Kayser, Stefan
Heigl, Franz
Sheriff, Ahmed
author_facet Torzewski, Jan
Brunner, Patrizia
Ries, Wolfgang
Garlichs, Christoph D.
Kayser, Stefan
Heigl, Franz
Sheriff, Ahmed
author_sort Torzewski, Jan
collection PubMed
description C-reactive protein (CRP), the prototype human acute phase protein, may be causally involved in various human diseases. As CRP has appeared much earlier in evolution than antibodies and nonetheless partly utilizes the same biological structures, it is likely that CRP has been the first antibody-like molecule in the evolution of the immune system. Like antibodies, CRP may cause autoimmune reactions in a variety of human pathologies. Consequently, therapeutic targeting of CRP may be of utmost interest in human medicine. Over the past two decades, however, pharmacological targeting of CRP has turned out to be extremely difficult. Currently, the easiest, most effective and clinically safest method to target CRP in humans may be the specific extracorporeal removal of CRP by selective apheresis. The latter has recently shown promising therapeutic effects, especially in acute myocardial infarction and COVID-19 pneumonia. This review summarizes the pros and cons of applying this novel technology to patients suffering from various diseases, with a focus on its use in cardiovascular medicine.
format Online
Article
Text
id pubmed-8999816
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89998162022-04-12 Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons Torzewski, Jan Brunner, Patrizia Ries, Wolfgang Garlichs, Christoph D. Kayser, Stefan Heigl, Franz Sheriff, Ahmed J Clin Med Review C-reactive protein (CRP), the prototype human acute phase protein, may be causally involved in various human diseases. As CRP has appeared much earlier in evolution than antibodies and nonetheless partly utilizes the same biological structures, it is likely that CRP has been the first antibody-like molecule in the evolution of the immune system. Like antibodies, CRP may cause autoimmune reactions in a variety of human pathologies. Consequently, therapeutic targeting of CRP may be of utmost interest in human medicine. Over the past two decades, however, pharmacological targeting of CRP has turned out to be extremely difficult. Currently, the easiest, most effective and clinically safest method to target CRP in humans may be the specific extracorporeal removal of CRP by selective apheresis. The latter has recently shown promising therapeutic effects, especially in acute myocardial infarction and COVID-19 pneumonia. This review summarizes the pros and cons of applying this novel technology to patients suffering from various diseases, with a focus on its use in cardiovascular medicine. MDPI 2022-03-23 /pmc/articles/PMC8999816/ /pubmed/35407379 http://dx.doi.org/10.3390/jcm11071771 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Torzewski, Jan
Brunner, Patrizia
Ries, Wolfgang
Garlichs, Christoph D.
Kayser, Stefan
Heigl, Franz
Sheriff, Ahmed
Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
title Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
title_full Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
title_fullStr Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
title_full_unstemmed Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
title_short Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
title_sort targeting c-reactive protein by selective apheresis in humans: pros and cons
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999816/
https://www.ncbi.nlm.nih.gov/pubmed/35407379
http://dx.doi.org/10.3390/jcm11071771
work_keys_str_mv AT torzewskijan targetingcreactiveproteinbyselectiveapheresisinhumansprosandcons
AT brunnerpatrizia targetingcreactiveproteinbyselectiveapheresisinhumansprosandcons
AT rieswolfgang targetingcreactiveproteinbyselectiveapheresisinhumansprosandcons
AT garlichschristophd targetingcreactiveproteinbyselectiveapheresisinhumansprosandcons
AT kayserstefan targetingcreactiveproteinbyselectiveapheresisinhumansprosandcons
AT heiglfranz targetingcreactiveproteinbyselectiveapheresisinhumansprosandcons
AT sheriffahmed targetingcreactiveproteinbyselectiveapheresisinhumansprosandcons